

Stanford



Idit Sagiv Barfi

Instructor, Medicine - Oncology

Bio

ACADEMIC APPOINTMENTS

- Instructor, Medicine - Oncology

HONORS AND AWARDS

- Summer scholarship for excellence, HUJI (2003)
- Noah Lihtenstein prize, HUJI (2009)
- Travel grant for the 14th international congress of immunology in Kobe, Japan, ICI (2010)
- Travel grant for the 3rd German-Israeli Cancer Research School in Pichl, Austria., DKFZ (2010)
- Maydan foundation scholarship for excellence in PhD studies, Maydan foundation (2010-2012)
- Kaye innovation award, Isaac Kaye foundation (2012)
- Winning poster, Stanford University Medicine/Oncology (2013)
- Abstract achievement award, American Society of Hematology (2015)
- Abstract achievement award, ASH meeting on Lymphoma biology (2016)
- Scholar-in-Training Award, American Association for Cancer Research (2016)
- The Henzl-Gabor Travel Grant, Stanford University (2016)
- Arthur L. Irving Family Foundation Cancer Immunology Symposium- attendee, The Arthur L. Irving Family Foundation, CRI (2020)
- Fellow to Faculty Scholar award, American Society of Hematology (2020-2022)

PROFESSIONAL EDUCATION

- Ph.D, Hebrew University Of Jerusalem , Biochemistry, immunology (2012)

PATENTS

- Idit Sagiv Barfi, Ronald Levy, Betty Chang, Patrick Ng, Kohrt Holbrook. "United States Patent 12016500743A1 Treatment using bruton's tyrosine kinase inhibitors and immunotherapy", Pharmacyclics, Inc., The Board Of Trustees Of The Leland Stanford Junior University
- Idit Sagiv Barfi, Alexander Levitzki. "United States Patent 8,759,363 Quinazoline Based T Cell Proliferation Inhibitors", The Hebrew University of Jerusalem, Israel

Publications

PUBLICATIONS

- **Positron emission tomography imaging of activated T cells by targeting OX40 reveals spatiotemporal immune dynamics and predicts response to in situ tumor vaccination**
Mayer, A. T., Alam, I. S., Sagiv-Barfi, I., Wang, K., Vermesh, O., Czerwinski, D. K., Johnson, E. M., James, M. L., Levy, R., Gambhir, S. S.

AMER ASSOC CANCER RESEARCH.2018

- **S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock** *JOURNAL OF INFECTIOUS DISEASES*
Shir, A., Klein, S., Sagiv-Barfi, I., Geiger, T., Zigler, M., Langut, Y., Edinger, N., Levitzki, A.
2018; 217 (2): 288–97
- **Eradication of spontaneous malignancy by local immunotherapy.** *SCIENCE TRANSLATIONAL MEDICINE*
Sagiv-Barfi, I., Czerwinski, D., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., Levy, R.
2018; 10 (426)
- **Eradication of spontaneous malignancy by local immunotherapy.** *Science translational medicine*
Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., Levy, R.
2018; 10 (426)
- **Imaging activated T cells predicts response to cancer vaccines.** *The Journal of clinical investigation*
Alam, I. S., Mayer, A. T., Sagiv-Barfi, I., Wang, K., Vermesh, O., Czerwinski, D. K., Johnson, E. M., James, M. L., Levy, R., Gambhir, S. S.
2018
- **Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo.** *Cell stem cell*
Kooreman, N. G., Kim, Y., de Almeida, P. E., Termglinchan, V., Diecke, S., Shao, N. Y., Wei, T. T., Yi, H., Dey, D., Nelakanti, R., Brouwer, T. P., Paik, D. T., Sagiv-Barfi, et al
2018
- **Holbrook Kohrt: In Memoriam (1977-2016).** *Clinical cancer research*
Houot, R., Pachynski, R., Czerwinski, D. K., Goldstein, M. J., Sagiv-Barfi, I., Brody, J., Müller, A. M., Marabelle, A.
2016; 22 (14): 3695-3696
- **Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.** *Blood*
Sagiv-Barfi, I., Kohrt, H. E., Burckhardt, L., Czerwinski, D. K., Levy, R.
2015; 125 (13): 2079-2086
- **Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.** *Proceedings of the National Academy of Sciences of the United States of America*
Sagiv-Barfi, I., Kohrt, H. E., Czerwinski, D. K., Ng, P. P., Chang, B. Y., Levy, R.
2015; 112 (9): E966-72
- **Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.** *Proceedings of the National Academy of Sciences of the United States of America*
Sagiv-Barfi, I., Kohrt, H. E., Czerwinski, D. K., Ng, P. P., Chang, B. Y., Levy, R.
2015; 112 (9): E966-72
- **Radiotherapy and Toll-Like Receptor Agonists** *SEMINARS IN RADIATION ONCOLOGY*
Marabelle, A., Filatenkov, A., Sagiv-Barfi, I., Kohrt, H.
2015; 25 (1): 34-39
- **Radiotherapy and toll-like receptor agonists.** *Seminars in radiation oncology*
Marabelle, A., Filatenkov, A., Sagiv-Barfi, I., Kohrt, H.
2015; 25 (1): 34-39
- **Targeting CD137 enhances the efficacy of cetuximab.** *journal of clinical investigation*
Kohrt, H. E., Colevas, A. D., Houot, R., Weiskopf, K., Goldstein, M. J., Lund, P., Mueller, A., Sagiv-Barfi, I., Marabelle, A., Lira, R., Troutner, E., Richards, L., Rajapaksa, et al
2014; 124 (6): 2668-2682
- **Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.** *Blood*
Kohrt, H. E., Sagiv-Barfi, I., Rafiq, S., Herman, S. E., Butchar, J. P., Cheney, C., Zhang, X., Buggy, J. J., Muthusamy, N., Levy, R., Johnson, A. J., Byrd, J. C.
2014; 123 (12): 1957-1960
- **Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.** *Blood*
Kohrt, H. E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., Waller, E., Ugolini, S., Vivier, et al

2014; 123 (5): 678-686

- **Depleting tumor-specific Tregs at a single site eradicates disseminated tumors** *JOURNAL OF CLINICAL INVESTIGATION*
Marabelle, A., Kohrt, H., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J., Brody, J., Luong, R., Rosenblum, M. D., Steinman, et al
2013; 123 (6): 2447-2463
- **Selective elimination of alloreactivity in vitro and in vivo while sparing other T-cell-mediated immune responses** *BONE MARROW TRANSPLANTATION*
Morecki, S., Gelfand, Y., Yacovlev, E., Eizik, O., Shabat, Y., Sagiv, I., Slavin, S.
2012; 47 (6): 838-845
- **Design, synthesis, and evaluation of quinazoline T cell proliferation inhibitors** *BIOORGANIC & MEDICINAL CHEMISTRY*
Sagiv-Barfi, I., Weiss, E., Levitzki, A.
2010; 18 (17): 6404-6413
- **A color discriminating broad range cell staining technology for early detection of cell transformation.** *Journal of carcinogenesis*
Sagiv, I., Idelevich, P., Rivkin, I., Margalit, R., Elkeles, A., Levitzki, A.
2009; 8: 16-?